Breaking News Instant updates and real-time market news.

SCHW

Charles Schwab

$38.17

0.07 (0.18%)

, DTE

DTE Energy

$93.42

1.14 (1.24%)

10:26
11/22/16
11/22
10:26
11/22/16
10:26

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Charles Schwab (SCHW) upgraded to Buy from Neutral at Citi with analyst William Katz citing the company's leverage to interest rates and its potential earnings power in 2018. 2. DTE Energy (DTE) upgraded to Buy from Neutral at BofA Merrill Lynch with analyst Brian Chin saying he believes DTE's Gas Storage and Pipeline net income will benefit under a Trump presidency. 3. Cooper-Standard (CPS) upgraded to Buy from Neutral at Goldman with analyst David Tamberrino saying valuation is not capturing operating improvements, incremental footprint restructuring activities, and significant growth in China. 4. GoDaddy (GDDY) upgraded to Buy from Neutral at B. Riley with analyst Sameet Sinha citing more confidence in the company's growth metrics. 5. Sunrun (RUN) upgraded to Overweight from Equal Weight at Barclays with analyst Jon Windham saying he sees potential for the company to take market share given the expected scaled-back operations at SolarCity following completion of the merger with Tesla (TSLA). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

SCHW

Charles Schwab

$38.17

0.07 (0.18%)

DTE

DTE Energy

$93.42

1.14 (1.24%)

CPS

Cooper-Standard

$94.14

1.09 (1.17%)

GDDY

GoDaddy

$36.09

0.77 (2.18%)

RUN

Sunrun

$4.82

-0.16 (-3.21%)

  • 13

    Dec

SCHW Charles Schwab
$38.17

0.07 (0.18%)

10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/22/16
SBSH
11/22/16
DOWNGRADE
Target $24
SBSH
Neutral
AllianceBernstein downgraded to Neutral from Buy at Citi
Citi analyst William Katz downgraded AllianceBernstein (AB) to Neutral saying the recent rally in shares "tempers residual upside" while its MLP structure limits potential tax-related earnings accretion. The analyst keeps a $24 price target for the shares. Katz this morning also upgraded Charles Schwab (SCHW) to Buy.
11/22/16
SBSH
11/22/16
UPGRADE
Target $44
SBSH
Buy
Charles Schwab upgraded to Buy from Neutral at Citi
Citi analyst William Katz upgraded Charles Schwab to Buy citing the company's leverage to interest rates and its potential earnings power in 2018. The analyst raised his price target for the shares to $44 from $35.
10/25/16
DBAB
10/25/16
NO CHANGE
Target $33
DBAB
Buy
E-Trade, Ameritrade deal less likely over next year, says Deutsche Bank
Deutsche Bank analyst Brian Bedell believes TD Ameritrade's (AMTD) acquisition of Scottrade makes an E-Trade (ETFC)/Ameritrade deal "much less likely" for at least 12-18 months. The analyst expects pricing competition to rise as e-brokers look to attract Scottrade and Ameritrade customers via various discounts. Bedell views Charles Schwab (SCHW) as the best positioned in this environment. The analyst has Buy ratings on Schwab and E-Trade and a Hold rating on TD Ameritrade.
DTE DTE Energy
$93.42

1.14 (1.24%)

11/22/16
BOFA
11/22/16
UPGRADE
BOFA
Buy
DTE Energy upgraded to Buy from Neutral at BofA/Merrill
11/14/16
JEFF
11/14/16
INITIATION
Target $102
JEFF
Buy
DTE Energy initiated with a Buy at Jefferies
Jefferies analyst Anthony Crowdell started DTE Energy with a Buy rating and $102 price target.
01/13/16
01/13/16
UPGRADE

On The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ACE Limited (ACE) upgraded to Outperform from Market Perform at Wells Fargo... BHP Billiton (BHP) upgraded to Overweight from Equal Weight at Morgan Stanley... Black Knight Financial (BKFS) upgraded to Buy from Neutral at BofA/Merrill... Brookfield Infrastructure (BIP) upgraded to Strong Buy at Raymond James... CME Group (CME) upgraded to Overweight from Neutral at JPMorgan... Canadian National (CNI) upgraded to Buy from Hold at Canaccord... Cheniere Energy (LNG) upgraded to Buy from Neutral at Citi... Cornerstone OnDemand (CSOD) upgraded to Outperform at FBR Capital... DTE Energy (DTE) upgraded to Overweight from Equal Weight at Barclays... E.ON AG (EONGY) upgraded to Buy from Neutral at UBS... Eldorado Gold (EGO) upgraded to Buy from Hold at Canaccord... Escalade (ESCA) upgraded to Buy from Hold at Wunderlich... Ferro (FOE) upgraded to Buy from Accumulate at Seaport Global... Five Below (FIVE) upgraded on traffic trends, macro tailwinds at Stifel... L'Oreal (LRLCY) upgraded to Outperform from Neutral at Credit Suisse... Marsh & McLennan (MMC) upgraded to Outperform from Market Perform at Keefe Bruyette... Mercer (MERC) upgraded to Buy from Neutral at Sidoti... Meritage Homes (MTH) upgraded to Overweight from Neutral at JPMorgan... Microsoft (MSFT) upgraded to Overweight from Equal Weight at Morgan Stanley... Middleby (MIDD) upgraded to Outperform from Neutral at Macquarie... Mirati Therapeutics (MRTX) upgraded to Buy from Neutral at Citi... Morgan Stanley sees Microsoft (MSFT) set up for earnings growth, ups to buy... Praxair (PX) upgraded to Accumulate from Neutral at Seaport Global... PrivateBancorp (PVTB) upgraded to Outperform from Sector Perform at RBC Capital... PulteGroup (PHM) upgraded to Overweight from Neutral at JPMorgan... Quaker Chemical (KWR) upgraded to Accumulate from Neutral at Seaport Global... Qualcomm (QCOM) upgraded to Positive at Susquehanna... Sallie Mae (SLM) upgraded to Buy from Neutral at Goldman... Swedbank (SWDBY) upgraded to Neutral from Underperform at Credit Suisse... Synchrony (SYF) upgraded to Conviction Buy from Buy at Goldman... TD Ameritrade (AMTD) upgraded to Buy named a top pick at BofA/Merrill... Torchmark (TMK) upgraded to Outperform from Market Perform at Wells Fargo... Tyco (TYC) upgraded to Neutral from Sell at UBS... U.S. Silica (SLCA) upgraded to Buy from Neutral at SunTrust... Verastem (VSTM) upgraded to Speculative Buy from Hold at Cantor... WCI Communities (WCIC) upgraded to Neutral from Underweight at JPMorgan.
11/22/16
BOFA
11/22/16
UPGRADE
BOFA
Buy
DTE Energy upgraded to Buy at BofA/Merrill
As previously reported, BofA/Merrill upgraded DTE Energy to Buy from Neutral and raised its price target to $99 from $97. Analyst Brian Chin believes DTE's Gas Storage and Pipeline net income will benefit under a Trump presidency.
CPS Cooper-Standard
$94.14

1.09 (1.17%)

11/22/16
GSCO
11/22/16
UPGRADE
GSCO
Buy
Cooper-Standard upgraded to Buy from Neutral at Goldman
Goldman analyst David Tamberrino upgraded Cooper-Standard to Buy and raised its price target to $100 from $99. The analyst said valuation is not capturing operating improvements, incremental footprint restructuring activities, and significant growth in China. He expects outsized margin improvement and said the company continues to win new business on current product as well as new technology where it has pricing power.
11/03/16
ROTH
11/03/16
NO CHANGE
Target $115
ROTH
Buy
Cooper-Standard recent weakness appears overdone, says Roth Capital
Roth Capital analyst Matt Koranda says that while he can appreciate investors' increased level of caution on OEM suppliers, recent weakness in Cooper-Standard's shares appears overdone as the company's near-term growth and margin expansion rely more on vehicle mix, increasing penetration in Asia, and implementation of self-help margin improvement initiatives. The analyst reiterates a Buy rating and $115 price target on the shares.
10/19/16
10/19/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) downgraded to Market Perform from Outperform at FBR Capital with analyst Paul Miller saying the shares will be range-bound pending greater clarity into the ongoing regulatory investigations and recently announced independent audit. 2. Cree (CREE) downgraded to Equal Weight from Overweight at Stephens with analyst Harsh Kumar citing his belief that the growth as well margin progression has been slower than expected since the ERP issues that hit the company earlier this year. 3. Norwegian Cruise Line (NCLH) downgraded to Hold from Buy at SunTrust with analyst Patrick Scholes citing a recent pricing survey that indicates a broad based slowdown across all global regions. 4. Genesco (GCO) downgraded to Buy from Strong Buy at CL King. 5. Cooper-Standard (CPS) downgraded to Hold from Buy at Jefferies with analyst Bret Jordan saying the valuation looks full with the shares up 23% year-to-date. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/19/16
JEFF
10/19/16
DOWNGRADE
Target $105
JEFF
Hold
Cooper-Standard downgraded to Hold from Buy at Jefferies
Jefferies analyst Bret Jordan downgraded Cooper-Standard to Hold saying the valuation looks full with the shares up 23% year-to-date. The analyst also expects decelerating North America market growth due to cyclical slowdown. He keeps a $105 price target for the stock.
GDDY GoDaddy
$36.09

0.77 (2.18%)

11/22/16
RILY
11/22/16
UPGRADE
Target $45
RILY
Buy
GoDaddy upgraded to Buy from Neutral at B. Riley
B. Riley analyst Sameet Sinha upgraded GoDaddy to Buy citing more confidence in the company's growth metrics. He highlights GoDaddy's model evolution to mid-sized customers and enhanced products. The analyst raised his price target for the shares to $45 from $33.50.
11/03/16
OPCO
11/03/16
NO CHANGE
Target $43
OPCO
Outperform
GoDaddy price target raised to $43 from $37 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for GoDaddy to $43 from $37 following "solid" Q3 results. The analyst expects margin to continue to improve on more proactive customer engagement and more effective marketing, and highlights the company's predictability, scale advantage and scalability. Helfstein reiterates an Outperform rating on the shares.
11/01/16
11/01/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. MasterCard (MA) downgraded to Neutral from Buy at Guggenheim. 2. L Brands (LB) downgraded to Neutral from Buy at Mizuho with analyst Betty Chen saying the company's third quarter earnings per share miss "demonstrates the severity of the challenges" it's facing, and she believes that its outlook is "cloudy." 3. GoDaddy (GDDY) downgraded to Neutral from Buy at Monness Crespi with analyst James Cakmak citing valuation and saying he sees limited upside to estimates but expects another solid quarter. 4. Baker Hughes (BHI) downgraded to Outperform from Strong Buy at Raymond James. 5. Level 3 (LVLT) downgraded to Neutral from Buy at Goldman, to Sector Perform from Outperform at RBC Capital, and to Hold from Buy at Jefferies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/18/16
RBCM
11/18/16
NO CHANGE
RBCM
Internet stock weakness creates buying opportunity, says RBC Capital
EBC Capital analyst Mark Mahaney says that the 5%-10% decline in Internet stocks since the election has created more attractive long-term opportunities. The analyst does not expect the Trump Administration's policies to have a major impact on the fundamentals of the Internet sector. His favorite large-cap names in the sector are, in order, Netflix (NFLX), Facebook (FB), and Priceline (PCLN). His favorite small-cap names are, in order, Yelp (YELP), Criteo (CRTO), and GoDaddy (GDDY).
RUN Sunrun
$4.82

-0.16 (-3.21%)

11/10/16
JMPS
11/10/16
DOWNGRADE
JMPS
Market Perform
Sunrun downgraded to Market Perform from Outperform at JMP Securities
10/06/16
GSCO
10/06/16
UPGRADE
GSCO
Buy
Sunrun upgraded to Buy from Neutral at Goldman
Goldman analyst Brian Lee upgraded Sunrun to Buy from Neutral with a $10 price target, citing "above-market growth potential."
11/22/16
LEHM
11/22/16
UPGRADE
Target $7
LEHM
Overweight
Sunrun upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Jon Windham upgraded Sunrun (RUN) to Overweight following the company's Q3 results with an unchanged price target of $7. The analyst sees potential for the company to take market share given the expected scaled-back operations at SolarCity following completion of the merger with Tesla (TSLA). A significant amount of negative sentiment has been priced into Sunrun with the stock down 25% over the last month, Windham tells investors in a research note.
11/09/16
BOFA
11/09/16
DOWNGRADE
BOFA
Neutral
Sunrun downgraded to Neutral from Buy at BofA/Merrill

TODAY'S FREE FLY STORIES

SBUX

Starbucks

$57.21

-1.3 (-2.22%)

17:09
12/04/16
12/04
17:09
12/04/16
17:09
Conference/Events
Starbucks to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CS

Credit Suisse

$13.39

-0.34 (-2.48%)

17:03
12/04/16
12/04
17:03
12/04/16
17:03
Conference/Events
Credit Suisse to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

, SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

17:02
12/04/16
12/04
17:02
12/04/16
17:02
Hot Stocks
Takeda Pharma, Seattle Genetics reports Phase 3 ADCETRIS data »

Takeda Pharmaceutical…

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CGEN

Compugen

$5.95

0.1 (1.71%)

16:59
12/04/16
12/04
16:59
12/04/16
16:59
Conference/Events
Compugen to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

QURE

uniQure

$5.68

-0.31 (-5.18%)

16:56
12/04/16
12/04
16:56
12/04/16
16:56
Hot Stocks
uniQure reports data on AMT-060 in hemophilia B »

uniQure announced new and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 08

    Dec

RGLS

Regulus

$2.50

0.1 (4.17%)

16:53
12/04/16
12/04
16:53
12/04/16
16:53
Conference/Events
Regulus to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

PBI

Pitney Bowes

$14.63

0.1 (0.69%)

16:52
12/04/16
12/04
16:52
12/04/16
16:52
Conference/Events
Pitney Bowes to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:43
12/04/16
12/04
16:43
12/04/16
16:43
Hot Stocks
Seattle Genetics reports Phase 1b vadastuximab talirine data, plans Ph. 2 trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

16:38
12/04/16
12/04
16:38
12/04/16
16:38
Hot Stocks
Novartis reports Phase 2 SEG101 data »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PFE

Pfizer

$31.63

0.17 (0.54%)

16:33
12/04/16
12/04
16:33
12/04/16
16:33
Hot Stocks
Pfizer reports Phase 2 glasdegib data »

Pfizer announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

EKSO

Ekso Bionics

$4.27

-0.11 (-2.51%)

16:30
12/04/16
12/04
16:30
12/04/16
16:30
Conference/Events
Ekso Bionics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ADSK

Autodesk

$70.57

1.35 (1.95%)

16:24
12/04/16
12/04
16:24
12/04/16
16:24
Conference/Events
Autodesk to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 09

    Jan

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:23
12/04/16
12/04
16:23
12/04/16
16:23
Hot Stocks
Seattle Genetics reports Phase 2 ADCETRIS lymphoma data, says discontinues trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

FTI

FMC Technologies

$35.60

0.9 (2.59%)

, TKPPY

Technip

$17.80

0.45 (2.59%)

16:21
12/04/16
12/04
16:21
12/04/16
16:21
Conference/Events
Technip to host special shareholder meeting »

Special Shareholder…

FTI

FMC Technologies

$35.60

0.9 (2.59%)

TKPPY

Technip

$17.80

0.45 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

TKPPY

Technip

$17.80

0.45 (2.59%)

, FTI

FMC Technologies

$35.60

0.9 (2.59%)

16:14
12/04/16
12/04
16:14
12/04/16
16:14
Conference/Events
FMC Technologies to host special shareholder meeting »

Special Shareholder…

TKPPY

Technip

$17.80

0.45 (2.59%)

FTI

FMC Technologies

$35.60

0.9 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

16:04
12/04/16
12/04
16:04
12/04/16
16:04
Hot Stocks
Alnylam reports interim Phase 1 data on fitusiran »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADRO

Aduro Biotech

$10.80

0.25 (2.37%)

16:01
12/04/16
12/04
16:01
12/04/16
16:01
Hot Stocks
Aduro Biotech reports presentation of BION-1301 data »

Aduro Biotech announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$6.70

-0.5 (-6.94%)

15:59
12/04/16
12/04
15:59
12/04/16
15:59
Hot Stocks
Trillium Therapeutics reports presentation of TTI-621 data »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BLUE

bluebird bio

$69.75

1.1 (1.60%)

15:47
12/04/16
12/04
15:47
12/04/16
15:47
Hot Stocks
bluebird bio reports new data from HGB-205 study of LentiGlobin »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

15:43
12/04/16
12/04
15:43
12/04/16
15:43
Hot Stocks
Bellicum Pharmaceuticals reports updated data from BPX-501 study »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

15:39
12/04/16
12/04
15:39
12/04/16
15:39
Hot Stocks
Alnylam reports Phase 1 givosiran data, says plans Phase 3 study late 2017 »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$31.63

0.17 (0.54%)

, ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

15:32
12/04/16
12/04
15:32
12/04/16
15:32
Hot Stocks
Spark Therapeutics, Pfizer report updated preliminary data on SPK-9001 »

Spark Therapeutics (ONCE)…

PFE

Pfizer

$31.63

0.17 (0.54%)

ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 06

    Dec

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

15:26
12/04/16
12/04
15:26
12/04/16
15:26
Conference/Events
Seattle Genetics to hold an investor reception »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$27.20

-0.1 (-0.37%)

15:21
12/04/16
12/04
15:21
12/04/16
15:21
Conference/Events
Roche to hold an analyst meeting »

Analyst Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

15:17
12/04/16
12/04
15:17
12/04/16
15:17
Hot Stocks
Juno Therapeutics reports Phase 1 data on JCAR014 »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.